Home›Leflunomide›Leflunomide + Duloxetine

Does Leflunomide Interact with Duloxetine?

The leflunomide label names duloxetine among CYP1A2 substrates whose exposure may decrease. It attributes this effect to teriflunomide, leflunomide’s active metabolite.

Label evidence and limitations

Named-drug label evidence. The label supports this exposure warning. It does not establish CDI’s moderate category or predict the effect for an individual patient.

Product scope: Oral leflunomide tablets; CYP1A2 substrate interaction.

Read the DailyMed label: These highlights do not include all the information needed to use LEFLUNOMIDE TABLETS safely and effectively. See full prescribing information for LEFLUNOMIDE TABLETS. LEFLUNOMIDE tablets, for oral use Initial U.S. Approval: 1998
Section: 7 Drug Interactions — CYP1A2 substrates. Compared version 8, label date 2024-08-20. The linked label may be updated after this comparison.

This comparison uses the label identifier saved with the CDI record. The compared version may be newer than the original extraction.

AI-assisted source comparison dated 2026-10-16. This is a comparison of label text, not independent clinical review or an individual safety assessment. CDI's stored severity category is not an FDA-assigned rating. Confirm your exact medicines and formulations with your pharmacist or prescriber before changing treatment.

Stored CDI classification: Moderate
Leflunomide Class: Antirheumatic Agent
Management: Confirm exact products with your pharmacist
Data Source: Product label via NLM DailyMed

What To Tell Your Doctor or Pharmacist

If you are taking Leflunomide and your doctor is considering prescribing Duloxetine (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Never stop or change either medication without first consulting your healthcare provider

💊 Leflunomide(Arava)+💊 Duloxetine(Irenka)

Severity & Interaction Details

🟡

Stored CDI classification: moderate

Named-drug label evidence

The label supports this exposure warning. It does not establish CDI’s moderate category or predict the effect for an individual patient.

Stored CDI scale

MinorContra

On record

Yes

Drug A class

Antirheumatic Agent

Drug B class

—

Source

NLP:leflunomide

How to interpret this source comparison

The label supports this exposure warning. It does not establish CDI’s moderate category or predict the effect for an individual patient.

About Leflunomide and Duloxetine

Leflunomide is an Antirheumatic Agent. You may recognize them by the brand names Arava and Irenka. Both Leflunomide and Duloxetine carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:leflunomide

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Leflunomide and Duloxetine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.